Pharmacological manipulation of mTOR might alleviate the metabolic effects of ECHS1‐deficiency paralleling the results obtained in other genetic forms of mitochondrial‐related neurodegeneration,19 including Leigh Syndrome.20 The gene discussed is MTOR; the disease is Leigh syndrome.